Skip to content

Advertisement

  • Invited speaker presentation
  • Open Access

PReS13-SPK-1579: Biologic agents for the treatment of rheumatic diseases

  • 1
Pediatric Rheumatology201311 (Suppl 2) :I27

https://doi.org/10.1186/1546-0096-11-S2-I27

  • Published:

Keywords

  • Public Health
  • Rheumatoid Arthritis
  • Arthritis
  • Methotrexate
  • Rheumatic Disease

Since the middle 1990s biologics have been available for rheumatic diseases. The initial experiments showed efficacy for symptoms and signs but concern was expressed about tachyphylaxis and absence of a true DMARD effect. Combining the antibodies with methotrexate answered some of these criticisms and since that time the number of agents available for rheumatoid arthritis, psoriatic arthritis and spondyloarthropathy has grown.

It is clear these agents work, what is less clear is how they should be used to produce optimum cost benefit. The ever expanding market has attracted a large number of pharmaceutical players to this area and this shows no sign of abating. Also there are number of new drugs including oral synthetic DMARDs becoming available.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
University of Leeds, Leeds, UK

Copyright

© Emery; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement